NWCI Stock Overview
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NewCardio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.00066 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -90.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.97% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NWCI | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 1.0% |
| 1Y | n/a | -9.6% | 21.9% |
Return vs Industry: Insufficient data to determine how NWCI performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how NWCI performed against the US Market.
Price Volatility
| NWCI volatility | |
|---|---|
| NWCI Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NWCI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NWCI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Jess Jones | n/a |
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company’s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data.
NewCardio, Inc. Fundamentals Summary
| NWCI fundamental statistics | |
|---|---|
| Market cap | US$40.00 |
| Earnings (TTM) | -US$8.84m |
| Revenue (TTM) | US$238.58k |
0.0x
P/S Ratio0.0x
P/E RatioIs NWCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWCI income statement (TTM) | |
|---|---|
| Revenue | US$238.58k |
| Cost of Revenue | US$167.77k |
| Gross Profit | US$70.81k |
| Other Expenses | US$8.91m |
| Earnings | -US$8.84m |
Last Reported Earnings
Sep 30, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NWCI perform over the long term?
See historical performance and comparison